Gene Variation Associated with OA in Women

OCTOBER 01, 2004

Researchers have found that a variant in the FRZB gene may increase the chances of osteoarthritis (OA) in women. The study involved analyzing deoxyribonucleic acid from pairs of siblings with OA. The results showed that a single nucleotide change in FRZB corresponded strongly with OA in women.

The FRZB gene codes for a protein that regulates a signaling pathway that is crucial in skeletal and joint development. The protein produced by the variant version of FRZB cannot perform the duties of the normal protein, according to the study reported recently in the Proceedings of the National Academy of Sciences. The researchers suggested that this variant version of FRZB may upset the proper development of joint cartilage and/or bone, making women with the variant more at risk for OA in the hip. If detected early, this gene variant may aid in prevention, treatment, and development of future treatments for OA.


Become a Respimat Top Performer 

Get to know RESPIMAT, the slow-moving mist inhaler from Boehringer Ingelheim Pharmaceuticals, Inc. 

Watch the RESPIMAT video and test your knowledge with a short multiple-choice quiz. When you get all the answers right, you’ll receive a certificate naming you a RESPIMAT T.O.P. Performer. Why not check it out today? 


Pharmacy Times Strategic Alliance

Pharmacist Education
Clinical features with downloadable PDFs

Next-Generation Pharmacist® Awards

3rd Annual Convenient Healthcare and Pharmacy Collaborative Conference

Personalize the information you receive by selecting targeted content and special offers.